Disclosure of Interests: J. E. Gottenberg, M. H. Buch, R. Caporali, G. C. Wright, T. Takeuchi, K. Kalunian, A. Pechonkina, Y. Guc, S. Rao, Y. Tan, R. Besuyen, M. C. Genovese, Strasburg Univ Hospital, Strasbourg, France; Univ of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom; Univ of Milan, Rheumatology Division, Hospital G. Pini-CTO, Milan, Italy; Grace C Wright MD PC, New York, NY, United States of America; Keio Univ, Tokyo, Japan; Univ of California San Diego, Division of Rheumatology, Allergy and Immunology, La Jolla, CA, United States of America; Gilead Sciences, Inc, Foster City, CA, United States of America; Galapagos BV, Leiden, Netherlands; Stanford Univ, Stanford, CA, United States of America


RESPONSE TO SMALL MOLECULES IS MOSTLY DRIVEN BY PATIENT GLOBAL ASSESSMENT OF DISEASE: A REAL WORLD OBSERVATION

C. Joseph1, S. M. Bilgrami2, L. Otteelli3, L. Gray4, W. Mitchell5, F. Wood6, M. Massarotti7, M. Bukhari8, 1, 2, 1. Lancaster University; Lancaster, United Kingdom; 2University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom

Background: Two Small molecules (Tofacitinib and Baricitinib) have been licensed in the UK for the use in rheumatoid arthritis. Their licensing came from several studies that showed good efficacy with baricitinib (1) study showing superior efficacy to adalimumab and tofacitinib showing non inferiority to TNF drugs (2). The response has also been shown in patient reported outcomes (find reference). Response when measure using the DAS score has two relatively subjective components (tender joints and patient global assessment) and two relatively objective components (Swollen joints and inflammation markers)

Objectives: To determine in a real world setting if the response to small molecules is mostly due to a drop in subjective or objective components of the DAS score

Methods: A retrospective chart review was done on all new starters on small molecules in a district hospital in the North of England. Data were collected at baseline, three months and six months from October 2018 to date. Drop in the components of the DAS28 score was calculated and overall drop in DAS28 was modelled as the explanatory variable using linear regression modelling. This was the done Adjusting for age gender and duration of disease. Sensitivity of the model was calculated using a logistic model of EULAR moderate/good response and using adjusted R squared estimates for linear model of improvement of the DAS28 score.

Results: 76 patients were included in the analysis from 85 starters on small molecules. 61 (71.8 %) were on baricitinib and the baseline median DAS28 score was .5.97 (IQR 5.35,6.55) The median drop at three months in the DAS28 was 2.42 (IQR 1.33,3.31), and at six months was 2.77 (IQR 2.01,3.83). There was numerical relative increased efficacy of baricitinib but this was not statistically significant (DAS drop at three months 2.54 IQR 1.73,3.09 vs 2.12 IQR 1.51,3.5). The relative contribution of the individual components of the DAS score to the drop ae in DAS are shown in table 1 below. Sensitivity analysis looking at predictors of a DAS drop of >0.6 confirmed this finding.

Table 1. Results of the adjusted linear regression models.

<table>
<thead>
<tr>
<th>Component of DAS dropping at three months</th>
<th>Adjusted R squared at 3 months</th>
<th>Adjusted R squared at 6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swollen Joints</td>
<td>0.12</td>
<td>0.05</td>
</tr>
<tr>
<td>Tender Joints</td>
<td>0.28</td>
<td>0.18</td>
</tr>
<tr>
<td>Patient global assessment</td>
<td>0.31</td>
<td>0.48</td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate</td>
<td>0.04</td>
<td>0.17</td>
</tr>
</tbody>
</table>

Conclusion: In this real world observational study, there was a good response to both small molecules with numerical better response to baricitinib. Tender joint count and patient global response accounted for more of the drop in DAS28 than swollen joints and inflammatory markers. At six months the biggest contributor to response was patient global assessment. This shows that JAK inhibitors might mediate their response initially mostly through pain modulation then by inflammation as exposure to drug continues.

References:

Disclosure of Interests: None declared

A VERY EARLY (7-28 DAYS) RESPONSE ON JAK INHIBITOR TOFACITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: EFFECT ON PAIN AND CENTRAL SENSITIZATION

A. Karateev1, E. Filatova2, E. Pogozheva1, V. Aimridzhanova1, E. Nasonov1, A. Lila1, V. Mazurov2, N. Lapkina3, G. Lukina4, T. Salnikova2, R. Samigulina2, D. Chakieva5, I. Marusenko6, O. Semagina2, M. Semchenkova1, S. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation; 2Medchnikov North-Western State Medical University, St-Petersburg, Russian Federation; 3Yaroslavl State Medical University, Yaroslavl, Russian Federation; 4Moscow Clinical Scientific and Practical Centre named after Loginov AS, Moscow, Russian Federation; 5Regional Clinical Hospital, Tula, Tula, Russian Federation; 6Petrozavodsk State University, Petrozavodsk, Russian Federation; 7Regional Clinical Hospital, Samara, Samara, Russian Federation; 8Smolensk State Medical University, Smolensk, Russian Federation

Background: The presence of central sensitization (CS) significantly burdens the course of rheumatoid arthritis (RA). JAK inhibitors block intracellular signal pathways including the ones responsible for synthesis of mediators and cytokines causing pain and CS. The application of JAK inhibitors is supposed to relieve pain and reduce CS severity promptly.

Objectives: To evaluate JAK inhibitor effect on pain and signs of CS in patients with active RA 7 and 28 days after the start of therapy.

Methods: Study group included 39 patients with RA, their age was 50.9±11.7, 79.5% of women, 89.7% of RF (+), DAS28 5.8±0.6, receiving DMARDs (methotrexate 82.0% and leflunomide 18.0%), who were administered with tofacitinib 5mg 2 times a day due to inefficacy or intolerance of genetically engineered biological drugs. There were assessed the pain severity using Brief pain inventory (BPI) questionnaire, the presence of neuropathic pain component (NPC) using PainDETECT questionnaire and signs of CS using Central Sensitisation Inventory (CSI) questionnaire at early time after tofacitinib administration.

Results: Patients initially experienced a severe pain – 5.72±2.21 according to the visual analogue scale (VAS), 53.8% had signs of central sensitization (CSI ≥ 40), 17.9% had NPC (PainDETECT >18), 7 days after tofacitinib intake there was statistically reliable reduction of pain severity – up to 4.37±2.2 (p=0.01), pain decrease of 29.4±17.9% (BPI), NPC – PainDETECT from 12.9±5.5 to 10.6±5.6 (p=0.047) and CS – CSI from 43.1±12.8 to 35.9±11.2 (p=0.01). The effect had increased after 28 days: pain level (VAS) was 2.84±1.57 (p=0.000), pain decrease of 43.6±29.6% (BPI), PainDETECT 29.8±12.4 (p=0.000), CSI 26.4±13.9 (p=0.000).

During this period there were no serious adverse reactions.

Conclusion: The application of JAK inhibitor tofacitinib allows to reach a fast analgesic effect, also due to impact on CS and NPC.

Source: National Registry patients with RA

Disclosure of Interests: Andrey Karateev: None declared, Ekaterina Filatova: None declared, Elena Pogozheva: None declared, Vera Aimridzhanova: None declared, Evgeny Nasonov: None declared, Alexander Lila: None declared, V Mazurov: None declared, N Lapkina: None declared, Galina Lukina Speakers bureau: Novartis, Pfizer, UCB, Abbvie, Biocad, MSD, Roche, Tatiana Salnikova: None declared, Ruzana Samigullina: None declared, Diana Chakieva: None declared, Irina Marusenko: None declared, Olga Semagina: None declared, Marina Semchenkova: None declared

DOI: 10.1136/annrheumdis-2020-eular.4029

SUSTAINABILITY OF RESPONSE TO UPADACITINIB AS MONOTHERAPY OR IN COMBINATION AMONG PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DMARDS

A. Kavanagh1, M. H. Buch2, B. Combe3, L. Besseste4, 5, I. H. Song5, Y. Song5, J. Suboticki5, P. Nash5, 1University of California San Diego, San Diego, United States of America; 2University of Manchester & NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; 3Lapeyronie Hospital, Montpellier University, Montpellier, France; 4Université Laval, Centre Hospitalier de l’Université Laval, Quebec, Canada; 5AbbVie Inc., North Chicago, United States of America; 6School of Medicine, Griffith University, Brisbane, Australia

Background: The primary treatment goal for patients (pts) with rheumatoid arthritis (RA) is a state of sustained clinical remission (REM) or low disease activity (LDA).1,2

Objectives: To assess the long-term sustainability of responses to upadacitinib (UPA), a JAK inhibitor, with or without background csDMARD(s) in pts with RA.

Methods: Data are from two phase 3 randomized, controlled trials of UPA in RA pts with roughly similar baseline disease characteristics: SELECT-NEXT enrolled pts with an inadequate response (IR) to csDMARD(s) on background stable csDMARD(s) receiving UPA 15mg or 30mg once daily or placebo for 12 weeks (wks);

References: